A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Titre officiel

A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Sommaire:

CC-90009-AML-001 est une étude de phase I menée en ouvert d’escalade et d’expansion de la dose auprès de sujets atteints de leucémie myéloblastique aigüe récidivante ou réfractaire

Description de l'essai

Primary Outcome:

• Dose- limiting toxicity (DLT)
• Non-tolerated dose (NTD)
• Maximum tolerated dose (MTD)

Secondary Outcome:

• Pharmacokinetics-Cmax
• Pharmacokinetics - AUC24
• Pharmacokinetics - tmax
• Pharmacokinetics - t 1/2
• Pharmacokinetics - CL
• Pharmacokinetics - Vss
• Preliminary efficacy of CC-90009
• Preliminary efficacy of CC-90009 - AML
• Preliminary efficacy of CC-90009 - MDS

Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion, first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute myeloid leukemia (AML) and relapsed or refractory high-risk myelodysplastic syndrome. The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-90009 in relapsed and refractory AML. The expansion part, (Part B), will further evaluate the safety and efficacy of CC-90009 administered at or below the maximum tolerated dose (MTD) in selected expansion cohorts of one or more dosing regimens in order to determine the recommended Phase 2 dose (RP2D) for subjects with relapsed or refractory AML and relapsed or refractory high-risk myelodysplastic syndrome.

Voir cet essai sur ClinicalTrials.gov